BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 16759051)

  • 1. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
    Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
    Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M; Keane N; McKinnon E; Phung S; Price P
    HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
    Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
    de Boer MG; Kroon FP; Kauffmann RH; Vriesendorp R; Zwinderman K; van Dissel JT
    Neth J Med; 2003 Dec; 61(12):408-12. PubMed ID: 15025416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
    Aberg JA; Williams PL; Liu T; Lederman HM; Hafner R; Torriani FJ; Lennox JL; Dube MP; MacGregor RR; Currier JS;
    J Infect Dis; 2003 Apr; 187(7):1046-52. PubMed ID: 12660918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort.
    Breaux K; Gadde S; Graviss EA; Rodriguez-Barradas MC
    AIDS Care; 2010 Jul; 22(7):886-94. PubMed ID: 20635253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy.
    Aberg JA; Chin-Hong PV; McCutchan A; Koletar SL; Currier JS
    Clin Infect Dis; 2002 Jul; 35(1):E8-E13. PubMed ID: 12060894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.
    Karakousis PC; Moore RD; Chaisson RE
    Lancet Infect Dis; 2004 Sep; 4(9):557-65. PubMed ID: 15336223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting.
    Manosuthi W; Chaovavanich A; Tansuphaswadikul S; Prasithsirikul W; Inthong Y; Chottanapund S; Sittibusaya C; Moolasart V; Termvises P; Sungkanuparph S
    J Infect; 2007 Nov; 55(5):464-9. PubMed ID: 17714788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.
    Lange CG; Valdez H; Medvik K; Asaad R; Lederman MM
    Clin Immunol; 2002 Feb; 102(2):154-61. PubMed ID: 11846457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency].
    Mary-Krause M; Rabaud C; Jouan M; Obadia M; de la Blanchardière A; Raffi F; May T
    Pathol Biol (Paris); 2000 Jun; 48(5):495-504. PubMed ID: 10949848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.
    Lederman HM; Williams PL; Wu JW; Evans TG; Cohn SE; McCutchan JA; Koletar SL; Hafner R; Connick E; Valentine FT; McElrath MJ; Roberts NJ; Currier JS;
    J Infect Dis; 2003 Dec; 188(12):1794-803. PubMed ID: 14673757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.
    Race EM; Adelson-Mitty J; Kriegel GR; Barlam TF; Reimann KA; Letvin NL; Japour AJ
    Lancet; 1998 Jan; 351(9098):252-5. PubMed ID: 9457095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
    Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.